Sosimerasib Sulfate

硫酸索西美雷塞

Report date: 2026/05/27 14:31:31
NME

Base Information

Drug NameSosimerasib Sulfate
Drug Alias Name硫酸索美来昔Sosimerasib Sulfate硫酸索西美雷塞sosimerasib索美来昔 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2026/02/25
Country/TerritoryUnited StatesPuerto RicoMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangxi Jemincare Group Co LtdShanghai Jiyu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHuya Bioscience International LlcZhejiang Hangyu Pharmaceutical Co LtdHuyabio International LLC +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A